



STEP THERAPY POLICY

- POLICY:** Topical Doxepin Step Therapy Policy
- Doxepin hydrochloride cream 5% (generic only)
 - Prudoxin™ (doxepin hydrochloride cream 5% – Mylan, generic)
 - Zonalon® (doxepin hydrochloride cream 5% – Mylan, generic)

REVIEW DATE: 04/15/2026

INSTRUCTIONS FOR USE

THE FOLLOWING COVERAGE POLICY APPLIES TO HEALTH BENEFIT PLANS ADMINISTERED BY CIGNA COMPANIES. CERTAIN CIGNA COMPANIES AND/OR LINES OF BUSINESS ONLY PROVIDE UTILIZATION REVIEW SERVICES TO CLIENTS AND DO NOT MAKE COVERAGE DETERMINATIONS. REFERENCES TO STANDARD BENEFIT PLAN LANGUAGE AND COVERAGE DETERMINATIONS DO NOT APPLY TO THOSE CLIENTS. COVERAGE POLICIES ARE INTENDED TO PROVIDE GUIDANCE IN INTERPRETING CERTAIN STANDARD BENEFIT PLANS ADMINISTERED BY CIGNA COMPANIES. PLEASE NOTE, THE TERMS OF A CUSTOMER'S PARTICULAR BENEFIT PLAN DOCUMENT [GROUP SERVICE AGREEMENT, EVIDENCE OF COVERAGE, CERTIFICATE OF COVERAGE, SUMMARY PLAN DESCRIPTION (SPD) OR SIMILAR PLAN DOCUMENT] MAY DIFFER SIGNIFICANTLY FROM THE STANDARD BENEFIT PLANS UPON WHICH THESE COVERAGE POLICIES ARE BASED. FOR EXAMPLE, A CUSTOMER'S BENEFIT PLAN DOCUMENT MAY CONTAIN A SPECIFIC EXCLUSION RELATED TO A TOPIC ADDRESSED IN A COVERAGE POLICY. IN THE EVENT OF A CONFLICT, A CUSTOMER'S BENEFIT PLAN DOCUMENT ALWAYS SUPERSEDES THE INFORMATION IN THE COVERAGE POLICIES. IN THE ABSENCE OF A CONTROLLING FEDERAL OR STATE COVERAGE MANDATE, BENEFITS ARE ULTIMATELY DETERMINED BY THE TERMS OF THE APPLICABLE BENEFIT PLAN DOCUMENT. COVERAGE DETERMINATIONS IN EACH SPECIFIC INSTANCE REQUIRE CONSIDERATION OF 1) THE TERMS OF THE APPLICABLE BENEFIT PLAN DOCUMENT IN EFFECT ON THE DATE OF SERVICE; 2) ANY APPLICABLE LAWS/REGULATIONS; 3) ANY RELEVANT COLLATERAL SOURCE MATERIALS INCLUDING COVERAGE POLICIES AND; 4) THE SPECIFIC FACTS OF THE PARTICULAR SITUATION. EACH COVERAGE REQUEST SHOULD BE REVIEWED ON ITS OWN MERITS. MEDICAL DIRECTORS ARE EXPECTED TO EXERCISE CLINICAL JUDGMENT WHERE APPROPRIATE AND HAVE DISCRETION IN MAKING INDIVIDUAL COVERAGE DETERMINATIONS. WHERE COVERAGE FOR CARE OR SERVICES DOES NOT DEPEND ON SPECIFIC CIRCUMSTANCES, REIMBURSEMENT WILL ONLY BE PROVIDED IF A REQUESTED SERVICE(S) IS SUBMITTED IN ACCORDANCE WITH THE RELEVANT CRITERIA OUTLINED IN THE APPLICABLE COVERAGE POLICY, INCLUDING COVERED DIAGNOSIS AND/OR PROCEDURE CODE(S). REIMBURSEMENT IS NOT ALLOWED FOR SERVICES WHEN BILLED FOR CONDITIONS OR DIAGNOSES THAT ARE NOT COVERED UNDER THIS COVERAGE POLICY (SEE "CODING INFORMATION" BELOW). WHEN BILLING, PROVIDERS MUST USE THE MOST APPROPRIATE CODES AS OF THE EFFECTIVE DATE OF THE SUBMISSION. CLAIMS SUBMITTED FOR SERVICES THAT ARE NOT ACCOMPANIED BY COVERED CODE(S) UNDER THE APPLICABLE COVERAGE POLICY WILL BE DENIED AS NOT COVERED. COVERAGE POLICIES RELATE EXCLUSIVELY TO THE ADMINISTRATION OF HEALTH BENEFIT PLANS. COVERAGE POLICIES ARE NOT RECOMMENDATIONS FOR TREATMENT AND SHOULD NEVER BE USED AS TREATMENT GUIDELINES. IN CERTAIN MARKETS, DELEGATED VENDOR GUIDELINES MAY BE USED TO SUPPORT MEDICAL NECESSITY AND OTHER COVERAGE DETERMINATIONS.

CIGNA NATIONAL FORMULARY COVERAGE:

OVERVIEW

Topical doxepin cream 5% (Prudoxin, Zonalon, generics) is indicated for the short-term (up to 8 days) **management of moderate pruritus** in adults **with atopic dermatitis or lichen simplex chronicus**.¹⁻³

Doxepin has H₁ and H₂ histamine receptor blocking actions, but the exact mechanism by which it exerts its antipruritic effect is unknown.¹⁻³ There are no data to establish the safety and effectiveness of doxepin cream when used for > 8 days. Furthermore, chronic use (beyond 8 days) may result in higher systemic levels and increased likelihood of contact sensitization.

Guidelines/Recommendations

Atopic Dermatitis

The American Academy and American College of Allergy, Asthma, and Immunology Joint Task Force guidelines for atopic dermatitis (eczema) [2023] recommend moisturizers as first-line therapy for mild disease.⁴ For refractory atopic dermatitis, guidelines recommend the addition of topical corticosteroids. Topical corticosteroids encompass a range of potencies selected based on disease severity and affected area. Topical doxepin is not addressed in the guidelines.

Lichen Simplex Chronicus

Topical corticosteroids are the current treatment of choice for lichen simplex chronicus to decrease inflammation and itch while concurrently softening the hyperkeratosis.⁵

POLICY STATEMENT

This program has been developed to encourage the use of two prescription Step 1 Products prior to the use of a Step 2 Product. If the Step Therapy rule is not met for a Step 2 Product at the point of service, coverage will be determined by the Step Therapy criteria below. All approvals are provided for 2 months in duration. In cases where the approval is authorized in months, 1 month is equal to 30 days.

Step 1: generic prescription topical corticosteroids

Step 2: Doxepin cream, Prudoxin cream, Zonalon cream

Topical Doxepin Step Therapy Policy product(s) is(are) covered as medically necessary when the following step therapy criteria is(are) met. Any other exception is considered not medically necessary.

CRITERIA

1. If the patient has tried two prescription Step 1 Products, approve a Step 2 Product. Note: Products with the same chemical entity and same strength should not be considered as separate products.

REFERENCES

1. Doxepin hydrochloride cream, 5% [prescribing information]. Parsippany, NJ: Teva; June 2021.
2. Prudoxin™ (doxepin hydrochloride) cream, 5% [prescribing information]. San Antonio, TX: DPT Laboratories; June 2017.
3. Zonalon® (doxepin hydrochloride cream, 5% [prescribing information]. San Antonio, TX: DPT Laboratories; June 2017.
4. AAAAI/ACAAI JTF Atopic Dermatitis Guideline Panel, Chu DK, Schneider L, et al. Atopic dermatitis (eczema) guidelines: 2023 American Academy of Allergy, Asthma and Immunology/American College of Allergy, Asthma and Immunology Joint Task Force on Practice Parameters GRADE- and

Institute of Medicine-based recommendations. *Ann Allergy Asthma Immunol.* 2024;132(3):274-312.

5. Moshkovich M, Andrade LF, Anderson M, Yosipovitch G. Lichen Simplex Chronicus: Clinical Perspectives and Emerging Therapeutic Strategies. *Am J Clin Dermatol.* 2025;26(6):895-903.

HISTORY

Type of Revision	Summary of Changes	Review Date
Annual Revision	No criteria changes.	05/22/2024
Annual Revision	No criteria changes.	05/07/2025
Early Annual Revision	The requirement that a patient has tried two Step 1 Products was clarified to add "prescription". Additionally, a Note was added to clarify that products with the same chemical entity and same strength should not be considered separate products.	04/15/2026

"Cigna Companies" refers to operating subsidiaries of The Cigna Group. All products and services are provided exclusively by or through such operating subsidiaries, including Cigna Health and Life Insurance Company, Connecticut General Life Insurance Company, Evernorth Behavioral Health, Inc., Cigna Health Management, Inc., and HMO or service company subsidiaries of The Cigna Group. © 2026 The Cigna Group.